Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer

Juan‐Cheng Yang, Ning Chang, Deng‐Chyang Wu, Wei‐Chung Cheng, Wei‐Min Chung, Wei‐Chun Chang, Fu‐Ju Lei, Chung‐Jung Liu, I‐Chen Wu, Hsueh‐Chou Lai, Wen‐Lung MaJournal of Cellular and Molecular Medicine 2019 · DOI

TL;DR

This study identifies aromatase (Ar) as a promising prognostic biomarker and therapeutic target in gastric cancer (GCa). Researchers found that inhibiting Ar with exemestane, particularly in combination with 5-fluorouracil (5-FU), significantly suppressed GCa cell growth and tumor progression in preclinical models, suggesting a novel therapeutic avenue for this challenging disease.

What Problem Does This Paper Address?

Gastric cancer (GCa) remains a significant cause of cancer-related mortality worldwide, often diagnosed at advanced stages with a poor prognosis and high recurrence rates. While 5-fluorouracil (5-FU) is a common chemotherapy, its effectiveness is limited, and there's a critical need for new, more effective therapeutic strategies. This paper investigates the potential of targeting aromatase (Ar), an enzyme known to play a role in hormone-dependent cancers like breast cancer, as a novel approach for GCa treatment. The challenge is to determine if Ar is relevant in GCa and if targeting it can lead to meaningful therapeutic benefits.

Methods

The researchers employed a multi-pronged approach:

  • Bioinformatics Analysis: They utilized a web-based Kaplan-Meier plotter to analyze existing cDNA microarray data from Caucasian GCa patients, correlating Ar gene expression with overall survival (OS) and progression-free survival (PFS) across various clinical scenarios (general, post-surgery, 5-FU treatment, HER2 status).
  • Tissue Microarray (TMA) Immunohistochemistry: They conducted a study on a cohort of Asian GCa patients using TMAs to assess Ar protein expression in tumor tissues and normal adjacent tissues, correlating it with clinical outcomes.
  • In Vitro Studies:
    • Cytotoxicity Assays (WST-1, IC50): They tested the efficacy of different aromatase inhibitors (ARIs), including type I (anastrozole, letrozole) and type II (exemestane), on GCa cell lines (AGS, SCM-1, MKN45) to determine their direct anti-cancer effects.
  • Colony Formation Assays: These assays evaluated the ability of GCa cells to form colonies after treatment with ARIs or after Ar knockdown, assessing long-term cell growth inhibition.
  • Gene Silencing (shRNA): They used short hairpin RNA (shRNA) to specifically knock down Ar expression in GCa cells to investigate the role of Ar itself, independent of its enzymatic activity.
  • Combination Therapy: They tested the synergistic effects of combining exemestane with 5-FU, and also the impact of adding estradiol (E2) to these combinations, to understand the underlying mechanisms.
  • In Vivo Studies (Xenograft Mouse Model): They implanted human GCa cells (MKN45) into immunocompromised mice and treated them with varying doses of exemestane alone and in combination with 5-FU to evaluate therapeutic efficacy and general toxicity.

Datasets

  • Caucasian GCa Patient Data: Publicly available cDNA microarray data from Caucasian GCa patients was used for bioinformatics analysis via the Kaplan-Meier plotter tool.
  • Asian GCa Patient Cohort: Primary tumor tissues from 220 GCa patients who underwent surgical resection at Kaohsiung Medical University Hospital between 2007 and 2014 were used to construct a tissue microarray (TMA) for immunohistochemistry.

Key Insights and Ideas

  • Ar as a Prognostic Biomarker: The study strongly suggests that Ar expression is not just present but actively contributes to GCa progression and poorer patient outcomes, making it a valuable prognostic marker.
  • Targeting Ar is a Viable Strategy: Unlike breast cancer, Ar targeting in GCa was unexplored. This research provides compelling preclinical evidence that inhibiting Ar can suppress GCa growth.
  • Exemestane's Superiority: Among the tested ARIs, exemestane (a type II, irreversible inhibitor) demonstrated superior cancer-suppressing efficacy compared to type I inhibitors like anastrozole and letrozole.
  • Non-Enzymatic Role of Ar: The finding that adding estradiol (E2) did not reverse the effects of exemestane or Ar knockdown suggests that Ar's role in GCa might extend beyond its enzymatic conversion of androgens to estrogens, potentially involving other signaling pathways.
  • Synergy with 5-FU: Combining exemestane with 5-FU showed a significant synergistic effect, enhancing tumor suppression and offering a promising combination therapy strategy, especially at reduced doses of 5-FU.

Key Results

  • Clinical Correlation: High Ar expression was associated with poorer prognosis in both Asian (TMA study) and Caucasian (bioinformatics) GCa patient populations across various clinical parameters.
  • In Vitro Efficacy: Exemestane exhibited significant cytotoxic effects on GCa cell lines, down-regulating Ar expression. Knocking down Ar with shRNA also suppressed GCa cell growth.
  • Combination Therapy Success: The combination of exemestane and 5-FU demonstrated synergistic inhibitory effects on GCa cell growth and colony formation in vitro.
  • In Vivo Tumor Suppression: In a xenograft mouse model, exemestane treatment alone reduced tumor size in a dose-dependent manner. The combination of exemestane and 5-FU achieved substantial tumor growth inhibition (up to ~90%) with no significant impact on body weight, indicating good tolerability.

Limitations and Future Work

  • Preclinical Focus: The study is primarily preclinical, relying on cell lines and xenograft models. While promising, these results need to be validated in human clinical trials.
  • Mechanism Elucidation: While the study suggests a non-enzymatic role for Ar, further research is needed to fully elucidate the precise molecular mechanisms by which Ar influences GCa progression and how exemestane exerts its effects.
  • Clinical Trial Encouragement: The authors explicitly encourage further pharmaceutical studies and human trials to explore the therapeutic potential of exemestane, particularly in combination with 5-FU, for GCa patients.
  • Potential Off-Target Effects: The paper briefly touches upon potential off-target mechanisms of ARIs, which warrant further investigation.

Summary updated

Abstract

CYP19A1/aromatase (Ar) is a prognostic biomarker of gastric cancer (GCa). Ar is a critical enzyme for converting androstenedione to oestradiol in the steroidogenesis cascade. For decades, Ar has been targeted with Ar inhibitors (ARIs) in gynaecologic malignancies; however, it is unexplored in GCa. A single-cohort tissue microarray examination was conducted to study the association between Ar expression and disease outcome in Asian patients with GCa. The results revealed that Ar was a prognostic promoter. Bioinformatics analyses conducted on a Caucasian-based cDNA microarray databank showed Ar to be positively associated with GCa prognosis for multiple clinical modalities, including surgery, 5-Fluorouracil (5-FU) for adjuvant chemotherapy, or HER2 positivity. These findings imply that targeting Ar expression exhibits a potential for fulfilling unmet medical needs. Hence, Ar-targeting compounds were tested, and the results showed that exemestane exhibited superior cancer-suppressing efficacy to other ARIs. In addition, exemestane down-regulated Ar expression. Ablating Ar abundance with short hairpin (sh)Ar could also suppress GCa cell growth, and adding 5-FU could facilitate this effect. Notably, adding oestradiol could not prevent exemestane or shAr effects, implicating a nonenzymatic mechanism of Ar in cancer growth. Regarding translational research, treatment with exemestane alone exhibited tumour suppression efficacy in a dose-dependent manner. Combining subminimal doses of 5-FU and exemestane exerted an excellent tumour suppression effect without influencing bodyweight. This study validated the therapeutic potentials of exemestane in GCa. Combination of metronomic 5-FU and exemestane for GCa therapy is recommended.
BibTeX
@article{yang2019preclinical,
  author = {Juan‐Cheng Yang and Ning Chang and Deng‐Chyang Wu and Wei‐Chung Cheng and Wei‐Min Chung and Wei‐Chun Chang and Fu‐Ju Lei and Chung‐Jung Liu and I‐Chen Wu and Hsueh‐Chou Lai and Wen‐Lung Ma},
  title = {{Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2019},
  doi = {10.1111/jcmm.14605},
}
Figure